Achievement of Hematology

<原著論文 英文>



1. Tadokoro J, Nakamura Y, Furusawa S, Mitani K.(2001): Low frequency of BCL10 gene mutations in B-cell non-Hodgkin's lymphoma. Int J Hematol 73, 222-225.

2. Yamamoto K, Nakamura Y, Arai H, Aoyagi M, Saito K, Furusawa S, Mitani K. (2001): Translocation (14;19)(q32;q13) detected by spectral karyotyping and lack of BCL3 rearrangement in CD5-positive B-cell lymphoma associated with hemophagocytic syndrome. Cancer Genet Cytogenet 130, 38-41.

3. Omine K, Ota J, Ueda M, Ueno S, Yoshida K, Yamashita Y, Kirito K, Imagawa S, Nakamura Y, Saito K, Akutsu M, Mitani K, Kano Y, Komatsu N, Ozawa K, Mano H. (2001): Characterization of stage progression in chronic myeloid leukemia by DNA microarray with purified hematopoietic stem cells. Oncogene 20, 8249-8257.

4. Tsurumi S, Nakamura Y, Maki M, Omine M, Fujita K, Okamura T, Niho Y, Hashimoto S, Kanno K, Suzuki K, Hangaishi A, Ogawa S, Hirai H, Mitani K.(2002): N-ras and p53 gene mutations in Japanese patients with myeloproliferative disorders. Am J Hematol 71, 131-133.

5. Arai H, Maki K, Waga K, Sasaki K, Nakamura Y, Imai Y, Kurokawa M, Hirai H, Mitani K. (2002): Functional regulation of TEL by p38-induced phosphorylation. Biochem Biophys Res Comm 299, 116-125.

6. Waga K, Nakamura Y, Maki K, Arai H, Yamagata T, Sasaki K, Kurokawa M, Hirai H, Mitani K. (2003): Leukemia-related transcription factor TEL accelerates differentiation of Friend erythroleukemia cells. Oncogene 22, 59-68.

7. Maki K, Arai H, Waga K, Sasaki K, Nakamura F, Imai Y, Kurokawa M, Hirai H, Mitani K. (2004): Leukemia-related transcription factor TEL is negatively regulated through ERK-induced phosphorylation. Mol. Cell. Biol. 24: 3227-3237.

8. Ichikawa M, Asai T, Saito T, Yamamoto G, Seo S, Yamazaki I, Yamagata T, Mitani K, Chiba S, Ogawa S, Kurokawa M, Hirai H. (2004): AML-1 is required for megakaryocytic maturation and lymphocytic differentiation, but not for maintenance of hematopoietic stem cells in adult hematopoiesis. Nat Med.10: 299-304. (Author list corrected in Erratum Nat Med. 11:102, 2005)

9. Sasaki K, Nakamura Y, Maki K, Waga K, Nakamura F, Arai H, Imai Y, Hirai H, Mitani K.(2004): Functional analysis of a dominant-negative ΔETS TEL/ETV6 isoform. Biochem Biophys Res Comm 317, 1128-1137.

10. Gunji H, Waga K, Nakamura F, Maki K, Sasaki K, Nakamura Y, Mitani K. (2004): TEL/AML1 shows dominant-negative effects over TEL as well as AML1. Biochem Biophys Res Comm 322, 623-630.

11. Hori A, Kanda Y, Goyama S, Onishi Y, Komeno Y, Mitani K, Kishi Y, Ogawa S, Imatak, O, Chiba S, Kojima R, Hamaki T, Sakiyama M, Kami M, Makimoto ., Tanosaki R, Takaue Y, Hirai H. (2005): A prospective trial to evaluate the safety and efficacy of pravastatin for the treatment of refractory chronic graft-versus-host disease. Transplantation 79, 372-374.

12. Takahashi W, Sasaki K, Komatsu N, Mitani K.(2005): TEL/ETV6 accelerates erythroid differentiation and inhibits megakaryocytic maturation in a human leukemia cell line UT-7/GM. Cancer Sci 96, 340-348.

13. Maki K, Yamagata T, Asai T, Yamazaki I, Oda H, Hirai H, Mitani K. (2005): Dysplastic definitive hematopoiesis in AML1/Evi-1 knock-in embryos. Blood 106:2147-2155.

14. Nakamura F, Nakamura Y, Maki K, Sato Y, Mitani K.(2005): Cloning and characterization of a novel chimeric gene TEL/PTPRR in acute myelogenous leukemia with inv(12)(p13q13). Cancer Res 65:6612-6621.

15. Kojima R, Kami M, Kanda Y, Kusumi E, Kishi Y, Tanaka Y, Yoshioka S, Morishima S, Fujisawa S, Mori S, Kasai M, Hatanaka K, Tajima K,Kasai M, Mitani K,Ichinohe T, Hirai H, Taniguchi S, Sakamaki H, Harada M, Takaue Y.(2005): Comparison between reduced-intensity and conventional myeloablative allogeneic stem-cell transplantation in patients with hematologic malignancies aged between 50 and 59.Bone Marrow Transplant 36:667-674.

16. Ito Y, Ohyashiki K, Hirai H, Ogawa S, Mitani K, Hotta T, Bessho M, Naoe T, Mizoguchi M, Uchiyama T, Omine M.(2005): Assessment of the international prognostic scoring system for determining chemotherapeutic indications in myelodysplastic syndrome: Japanese retrospective multicenter study. Int J Hematol. 2005 Oct;82(3):236-42.

17. Miyawaki S, Sakamaki H, Ohtake S, Emi N, Yagasaki F, Mitani K, Matsuda S, Kishimoto Y, Miyazaki Y, Asou N, Matsushima T, Takahashi M, Ogawa Y, Honda, Ohno R.(2005): A randomized, postremission comparison for four courses of standard-dose consolidation therapy without maintenance therapy versus three courses of standard-dose consolidation therapy with maintenance therapy in adults with acute myelogenous leukemia. The Japan Adult leukemia Study Group AML97 study. Cancer 104:2726-2734.

18. Komeno Y, Kanda Y, Hamaki T, Mitani K, Iijima K, Ueyama F, Yoshihara S, Yuji K, Kim S, Ando T, Kami M, Yamamoto E, Hiruma K, Mori S, Hirai H, Sakamaki H.(2006): A randomized controlled trial to compare once- vesus twice-daily filgrastim for mobilization of peripheral blood stem cells from healthy donors. Biology of Blood and Marrow Transplantation 12; 408-413.

19. Maki K, Yamagata T, Yamazaki I, Od, H, Mitani K.(2006): Development of megakaryoblastic leukaemia in Runx1-Evi1 knock-in chimaeric mouse. Leukemia 20; 1458-1460.

20. Yamagata T, Maki K, Waga K, Mitani K.(2006): TEL/ETV6 induces apoptosis in 32D cells through p53-dependent pathways.Biochem Biophys Res Comm 347: 517-526.

21. Yamashita Y, Ohashi J, Hirai Y, Choi YL, Kaned, R, Fujiwara S, Arai Y, Akutsu M, Tsutsumi C, Miyazaki Y, Usuki K, Teramura M, Mitani K, Kano Y, O’Neil MC, Urabe A, Tomonaga M, Ozawa K, Mano H. (2006): Gene expression profiles of CD133-positive fractions predict the survival of individuals with acute myeloid leukemia. Cancer Genomics & Proteomics 3; 169-182.

22. Nakamura Y, Maki K, Sasaki K, Kitabayashi I, Mitani K. (2006): TEL/ETV6 binds to corepressor KAP1 via the HLH domain. Int J Hematol 84; 377-380.

23. Tokita K, Mak, K, Tadokoro J, Nakamura Y, Arai Y, Sasaki K, Eguchi-Ishimae M, Eguchi M, Mitani K. (2007): Chronic idiopathic myelofibrosis expressing a novel type of TEL-PDGFRB chimaera responded to imatinib mesylate therapy. Leukemia 21; 190-192.

24. Sanada M, Uike N, Ohyashiki K, Ozawa K, Lili W, Hangaishi A, Kanda Y, Chiba S, Kurokawa M, Omine M, Mitani K, Ogawa S. (2007): Unbalanced translocation der(1;7)(q10;p10) defines a unique clinicopathological subgroup of myeloid neoplasms. Leukemia 21; 992-997.

25. Yamagata T, Nakamura Y, Mitani K. (2007): Low expression of ETV6/TEL found in patients with myelodysplastic syndrome. Int J Hematol 86:282-285.

26. Tokita K, Maki K, Mitani K. (2007): RUNX1/EVI1 that blocks myeloid differentiation inhibits CCAAT-enhancer binding protein α function. Cancer Sci 98: 1752-1757.

27. Ishikawa T, Toyama K, Nakao S, Yoshida Y, Teramura M, Motoji T, Takatoku M, Kurokawa M, Mitani K, Uchiyam, T, Omine M. (2007): A prospective study of cyclosporine A treatment of patients with low-risk myelodysplastic syndrome: presence of CD55-CD59- blood cells predicts platelet response. Int J Hematol 86: 150-157.

28. Sasaki K, Yamagata T, Mitani K.(2008): Histone deacetylase inhibitors trichostatin A and valproic acid circumvent apoptosis in human leukemic cells expressing the RUNX1 chimera.Cancer Sci 99: 414-422.

29. Tasaka T, Tohyama K, Kishimoto M, Ohyashiki K, Mitani K, Hotta T, Kanamaru A, Okamoto S, Karasawa M, Kimura A, Tomonaga M, Uchiyama T, Ozawa K.(2008): Myelodysplastic syndrome with chromosome 5 abnormalities: A nationwide survey in Japan. Leukemia 22; 1871-1881.

30. Eguchi-Ishimae M, Eguchi M, Maki K, Porcher C, Shimizu R, Yamamoto M, Mitani K. (2009): Leukaemia-related transcription factor TEL/ETV6 expands erythroid precursors and stimulates haemoglobin synthesis. Cancer Sci 100: 689-697.

31. Eguchi-Ishimae M, Eguchi M, Ohyashik, K, Yamagata T, Mitani K. (2009): Enhanced expression of the EVI1 gene in NUP98/HOXA-expressing leukemia cells. Int J Hematol 89:253-256.

32. Kobayashi Y, Tobinai K, Takeshita A, Naito K, Asai O, Dobashi N, Furusawa S, Saito K, Mitani K, Morishima Y, Ogura M, Yoshiba F, Hotta H, Bessho M, Matsuda S, Takeuchi J, Miyawaki S, Naoe T, Usui N, Ohno R.(2009): I/II study of humanized anti-CD33 antibody conjugated with calicheamicin, gemtuzumab ozogamicin, in relapsed or refractory acute myeloid leukemia: Final results of Japanese multi-center cooperative study. Int J Hematol 89:460-469.

33. Sakamaki H, Miyawaki S, Ohtake S, Emi N, Yagasaki F, Mitani K, Matsuda S, Kishimoto Y, Miyazaki Y, Asou N, Takahashi M, Ogawa Y, Honda S, Ohno R. (2009): Allogeneic bone marrow transplantation versus chemotherapy as post-remission for intermediate or poor risk adult acute myeloid leukemia: results for the JALSG AML97 study. Int J Hematol 91, 284-292.

34. Akiyama N, Miyazawa K, Kanda Y, Tohyama K, Omine M, Mitani K, Ohyashiki K. (2010): Multicenter phase II trial of vitamine K2 plus 1a-hydroxyvitamine D3 combination therapy for low-risk myelodysplastic syndrome. Leuk Res 34.1151-1157.

35. Miyawaki S, Hatsumi N, Tamaki T, Naoe T, Ozawa K, Kitamura K, Karasuno T, Mitani K, Kodera Y, Yamagami T, Koga D. (2010): Prognostic potential of detection of WT1 mRNA level in peripheral blood in adult acute myeloid leukemia. Leuk & Lymph 51, 1855-1861.

36. Kanda Y, Yamashita T, Mori T, Ito T, Tajika K, Mori S, Sakura T, Hara M, Mitani K, Kurokawa M, Akashi K, harada M. (2010): A randomized controlled trial of plasma real-time PCR and antigenemia assay for monitoring CMV infection after unrelated BMT. Bone marrow Transplant 45, 1325-1332.

milk_btn_pagetop.png

<原著論文 和文>



1. 中村祐子、新井幸宏、郡司桐子、新井ほのか、中村文彦、半田智幸、田所治朗、牧 和宏、斉藤憲治、三谷絹子(2002):CAG療法が奏功した急性骨髄性白血病およびハイリスク骨髄異形成症候群症例におけるWT1遺伝子発現量の検討。臨床血液43:960-962.

2. 中村裕一、坂巻、向井陽美、小島 寛、富山順治、森慎一郎、比留間潔、中村典彦、豊田茂雄、浜口裕之、壇 和夫、三谷絹子、斉藤憲治(2004):多発性骨髄腫に対する自家末梢血幹細胞移植療法ー本邦でのプロトコールの実効性についての検討ー。 臨床血液45:524-529.

3. 宮脇修一、恵美宣彦、三谷絹子、大屋敷一馬、北村邦郎、森下剛久、小川啓恭、小松則夫、相馬俊裕、玉置俊治、小杉浩史、大西一功、溝口秀昭、平岡 締、小寺良尚、上田龍三、森島泰雄、中川雅史、飛田 規、杉本耕一、千葉 滋、井上信正、濱口元洋、古賀大輔、玉置広哉、直江知樹、杉村治夫、高久文磨(2004):急性骨髄性白血病(AML)191例の臨床経過とWT1 mRNAの発現量—全国23施設による共同研究—。臨床血液46:1279-1287.

milk_btn_pagetop.png

<症例報告 英文>



1. Nakamura Y, Nakazato H, Sato Y, Furusawa S, Mitani K. (2002): Expression of the TEL/EVI1 fusion transcript in a patient with chronic myelogenous leukemia with t(3;12)(q26;p13). Am J Hematol 69, 80-82.

2. Arai H, Arai Y, Haraguchi K, Nakamura Y, Tsurumi S, Maki K, Aoyagi A, Nakamura Y, Saito, K, Mitani K. (2002): Successful HLA-identical unrelated allogeneic bone marrow transplantation with a very low dose of stem cells for a patient with chronic myeloid leukemia in blast crisis. Leuk & Lymph 43, 2067-2069.

3. Nakamura F, Maki K, Arai Y, Nakamura Y, Mitani K. (2003): Monocytic leukemia with CALM/AF10 rearrangement showing mediastinal emphysema. Am J Hematol 72, 138-142.

4. Tomita S, Kojima M,Imamura J, Ueda Y, Koitabashi A, Suzuki Y, Nakamura Y, Mitani K, Terano A, Fujimori T. (2003): Diffuse nodular lymphoid hyperplasia of the large bowel without hypogammaglobulinemia or malabsorption syndrome. Int J Surg Pathol 10:297-302.

5. Tomita S, Kojima M, Imura J, Hor, H, Ueda Y, Koitabashi A, Suzuki Y, Nakamura Y, Nakamura Y, Mitani K, Terano A, Ohkura Y, Kawamata H, Fujimori T. (2003): Extranodal diffuse follicular center lymphoma mimicking mantle cell lymphoma of the intestine. Am J Hematol 74:287-289.

6. Nakamura F, Kishimoto Y, Hanada T, Arai Y, Mitani K. (2004): Myelodysplastic syndrome with central diabetes insipidus manifesting hypodipsic hypernatremia and dehydration. Am J Hematol 75, 213-216.

7. Arai Y, Tadokoro J, Mitani K.(2005):Ventricular tachycardia associated with infusion of rituximab in mantle cell lymphoma. Am J Hematol 78; 317-318.

8. Arai Y, Arai H, Aoyagi A., Kubota K, Kawamata H, Imai Y, Yamagata T, Mitani K. (2006): A solid tumor of donor cell-origin after allogeneic peripheral blood stem cell transplantation. Am J Transplant 6; 3042-3043.

9. Sasaki K, Tahara T, Mitani K.(2009): Presentation of familial Mediterranean fever in a heterozygous MEFV mutation triggered by immunosuppressive therapy for myelodysplastic syndrome. Int J Hematol 90, 91-93.

10. Handa T, Maki K, Segawa A, Masawa N, Mitani K.: In situ follicular lymphoma associated with progressive transformation of the germinal center. Int J Surg Pathol 19: 521-523, 2011.


milk_btn_pagetop.png

<症例報告 和文>



1. 仲村祐子、新井幸宏、中村文彦、牧 和宏、青柳有名、斉藤憲治、三谷絹子(2002):血小板減少に対する脾摘後に溶血が顕在化したCoombs陰性Evans症候群。臨床血液43:204-206.

2. 新井幸宏、半田智幸、中村文彦、高橋 渉、牧 和宏、三谷絹子(2002):慢性骨髄単球性白血病から移行したdouble t(3;21)を持つ急性骨髄単球性白血病。臨床血液43:865-867.

3. 鶴見茂治、中村裕一、田所治朗、新井幸宏、斉藤憲治、古澤新平、三谷絹子(2002):赤芽球癆の経過中に発症したsmall lymphocytic lymphoma。臨床血液43:1020-1022.

4. 高橋 渉、新井幸宏、中村文彦、仲村祐子、三谷絹子(2003):侵襲性真菌症による完全房室ブロックを併発した急性リンパ性白血病。臨床血液44:1032-1035.

5. 牧 和宏、中村文彦、郡司桐子、新井幸宏、三谷絹子(2003):初診時正常核型を示したPhiladelphia染色体陽性急性リンパ性白血病。臨床血液44:1110-1112.

6. 仲村祐子、新井幸宏、郡司桐子、新井ほのか、中村文彦、半田智幸、田所治朗、三谷絹子(2003):自己免疫性溶血性貧血に対するprednisoline療法後に顕在化した好酸球増加症候群。臨床血液44:1117-1119.

7. 新井幸宏、半田智幸、三谷絹子(2004):播種性血管内凝固症候群で発症した成人発症Still病。臨床血液45:316-318.

8. 半田智幸、新井幸宏、三谷絹子(2004):食道潰瘍を伴う腸管型Behçet病を併発した骨髄異形成症候群。臨床血液45:1135-1137.

9. 高橋 渉、新井幸宏、田所治朗、竹内賢吾、山形哲也、三谷絹子(2006):Imatinib mesylate投与によりPhiladelphia染色体陽性クローンが消失し陰性クローンが出現した急性骨髄単球性白血病。臨床血液47:111-113.

10. 田所治朗、新井幸宏、鴇田勝哉、礒 桐子、仲村祐子、牧 和宏、佐々木光、三谷絹子(2007):骨髄生検にて診断し得たAsian variantの血管内大細胞型B細胞リンパ腫。 臨床血液 48:61-63, 2007.

11. 新井ほのか、礒 桐子、新井幸宏、田所治朗、仲村祐子、山形哲也、三谷絹子(2009):全身性硬化症に合併した縦隔(胸腺)大細胞型B細胞リンパ腫。臨床血液50:97-101.

12. 新井ほのか、牧 和宏、田所治朗、仲村祐子、佐々木光、三谷絹子(2011):関節リウマチ患者に発症した節外性NK/T細胞リンパ腫。臨床血液52:551-555.



milk_btn_pagetop.png

<総説 英文>



1. Mitani, K.(2004): Molecular mechanisms of leukemogenesis by AML1/EVI-1. Oncogene 23, 4263-4269.

2. Yamagata, T., Maki, K., Mitani, K.(2005): Runx1/AML1 in normal and abnormal hematopoiesis. Int J Hematol 82, 1-8.

3. Maki, K., Yamagata, T., Mitani, K.(2008): Role of the RUNX1-EVI1 fusion gene in leukemogenesis. Cancer Sci 99, 1878-1883.


milk_btn_pagetop.png